- Home
- YUMC vs BIIB Comparison
YUMC vs BIIB Comparison
Compare YUMC & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YUMC
- BIIB
- Stock Information
- Founded
- YUMC 1987
- BIIB 1978
- Country
- YUMC China
- BIIB United States
- Employees
- YUMC N/A
- BIIB N/A
- Industry
- YUMC Restaurants
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- YUMC Consumer Discretionary
- BIIB Health Care
- Exchange
- YUMC Nasdaq
- BIIB Nasdaq
- Market Cap
- YUMC 18.2B
- BIIB 20.5B
- IPO Year
- YUMC N/A
- BIIB 1991
- Fundamental
- Price
- YUMC $46.69
- BIIB $140.60
- Analyst Decision
- YUMC Strong Buy
- BIIB Buy
- Analyst Count
- YUMC 3
- BIIB 27
- Target Price
- YUMC $49.57
- BIIB $220.50
- AVG Volume (30 Days)
- YUMC 2.6M
- BIIB 1.5M
- Earning Date
- YUMC 02-06-2025
- BIIB 02-12-2025
- Dividend Yield
- YUMC 1.54%
- BIIB N/A
- EPS Growth
- YUMC 18.27
- BIIB 40.28
- EPS
- YUMC 2.33
- BIIB 11.18
- Revenue
- YUMC $11,303,000,000.00
- BIIB $9,675,900,000.00
- Revenue This Year
- YUMC $10.26
- BIIB N/A
- Revenue Next Year
- YUMC $7.98
- BIIB $1.57
- P/E Ratio
- YUMC $20.06
- BIIB $12.65
- Revenue Growth
- YUMC 2.96
- BIIB N/A
- 52 Week Low
- YUMC $28.50
- BIIB $128.51
- 52 Week High
- YUMC $52.00
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- YUMC 48.36
- BIIB 44.88
- Support Level
- YUMC $47.00
- BIIB $135.02
- Resistance Level
- YUMC $49.87
- BIIB $141.69
- Average True Range (ATR)
- YUMC 1.40
- BIIB 4.00
- MACD
- YUMC -0.02
- BIIB 0.04
- Stochastic Oscillator
- YUMC 44.00
- BIIB 59.44
About YUMC Yum China Holdings Inc.
With almost 15,000 units and USD 12 billion in systemwide sales in 2023, Yum China is the largest restaurant operator in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (10,296 units) and Pizza Hut (3,312), but the company's portfolio also includes other brands such as Little Sheep, Taco Bell, Huang Ji Huang, and Lavazza (collectively representing more than 1,000 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.